1
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3
Chronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Tabarsi,P. , Afzal,G. , Eskandari,R. and Dastan,F. (2021). Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab. TANAFFOS (Respiration), 20(3), 188-191.
MLA
Tabarsi,P. , , Afzal,G. , , Eskandari,R. , and Dastan,F. . "Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab", TANAFFOS (Respiration), 20, 3, 2021, 188-191.
HARVARD
Tabarsi P., Afzal G., Eskandari R., Dastan F. (2021). 'Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab', TANAFFOS (Respiration), 20(3), pp. 188-191.
CHICAGO
P. Tabarsi, G. Afzal, R. Eskandari and F. Dastan, "Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab," TANAFFOS (Respiration), 20 3 (2021): 188-191,
VANCOUVER
Tabarsi P., Afzal G., Eskandari R., Dastan F. Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab. TANAFFOS (Respiration), 2021; 20(3): 188-191.
